The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 13, 2019

Filed:

Nov. 10, 2010
Applicants:

Dihua Yu, Houston, TX (US);

Xiaoyan Zhou, Shanghai, CN;

Yoichi Nagata, Tosu, JP;

Francisco J. Esteva, Bellaire, TX (US);

Aysegul A. Sahin, Houston, TX (US);

Inventors:

Dihua Yu, Houston, TX (US);

Xiaoyan Zhou, Shanghai, CN;

Yoichi Nagata, Tosu, JP;

Francisco J. Esteva, Bellaire, TX (US);

Aysegul A. Sahin, Houston, TX (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); C12Q 1/42 (2006.01); G01N 33/50 (2006.01); G01N 33/573 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12Q 1/42 (2013.01); G01N 33/5011 (2013.01); G01N 33/573 (2013.01); G01N 33/57415 (2013.01); C12Q 2600/106 (2013.01); Y10T 436/25 (2015.01);
Abstract

Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.


Find Patent Forward Citations

Loading…